Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Debt (2020 - 2025)

Myriad Genetics (MYGN) has disclosed Non-Current Debt for 4 consecutive years, with $119.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 202.78% to $119.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $119.9 million, a 202.78% increase, with the full-year FY2025 number at $119.9 million, up 202.78% from a year prior.
  • Non-Current Debt was $119.9 million for Q4 2025 at Myriad Genetics, roughly flat from $119.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $119.9 million in Q4 2025 to a low of $38.4 million in Q2 2023.
  • A 3-year average of $57.0 million and a median of $38.9 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: rose 1.04% in 2024, then skyrocketed 206.41% in 2025.
  • Myriad Genetics' Non-Current Debt stood at $38.5 million in 2023, then grew by 2.86% to $39.6 million in 2024, then surged by 202.78% to $119.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Non-Current Debt are $119.9 million (Q4 2025), $119.5 million (Q3 2025), and $59.3 million (Q1 2025).